| Year |
Citation |
Score |
| 2022 |
Van Stiphout CM, Luu AK, Viloria-Petit AM. Proteasome Inhibitors and Their Potential Applicability in Osteosarcoma Treatment. Cancers. 14. PMID 36230467 DOI: 10.3390/cancers14194544 |
0.31 |
|
| 2020 |
Asante EC, Pallegar NK, Hoffmann AJ, Viloria-Petit AM, Christian SL. Adipose Tissue from Lean and Obese Mice Induces a Mesenchymal to Epithelial Transition-Like Effect in Triple Negative Breast Cancers Cells Grown in 3-Dimensional Culture. International Journal of Molecular Sciences. 21. PMID 32899433 DOI: 10.3390/Ijms21176439 |
0.347 |
|
| 2019 |
Muñoz R, Hileeto D, Cruz-Muñoz W, Wood GA, Xu P, Man S, Viloria-Petit A, Kerbel RS. Suppressive impact of metronomic chemotherapy using UFT and/or cyclophosphamide on mediators of breast cancer dissemination and invasion. Plos One. 14: e0222580. PMID 31536574 DOI: 10.1371/Journal.Pone.0222580 |
0.617 |
|
| 2019 |
Mitz CA, Viloria-Petit AM. TGF-beta signalling in bovine mammary gland involution and a comparative assessment of MAC-T and BME-UV1 cells as in vitro models for its study. Peerj. 6. PMID 30671288 DOI: 10.7717/Peerj.6210 |
0.353 |
|
| 2018 |
Luu AK, Schott CR, Jones R, Poon AC, Golding B, Hamed R, Deheshi B, Mutsaers A, Wood GA, Viloria-Petit AM. An evaluation of TAZ and YAP crosstalk with TGFβ signalling in canine osteosarcoma suggests involvement of hippo signalling in disease progression. Bmc Veterinary Research. 14: 365. PMID 30477496 DOI: 10.1186/S12917-018-1651-5 |
0.343 |
|
| 2018 |
Pallegar NK, Garland CJ, Mahendralingam M, Viloria-Petit AM, Christian SL. A Novel 3-Dimensional Co-culture Method Reveals a Partial Mesenchymal to Epithelial Transition in Breast Cancer Cells Induced by Adipocytes. Journal of Mammary Gland Biology and Neoplasia. PMID 30474817 DOI: 10.1007/S10911-018-9420-4 |
0.393 |
|
| 2018 |
Christian SL, Pallegar NK, Brown RJ, Viloria-Petit AM. Collagen overlays can inhibit leptin and adiponectin secretion but not lipid accumulation in adipocytes. Peerj. 6: e4641. PMID 29719734 DOI: 10.7717/Peerj.4641 |
0.302 |
|
| 2018 |
Golding B, Luu A, Jones R, Viloria-Petit AM. The function and therapeutic targeting of anaplastic lymphoma kinase (ALK) in non-small cell lung cancer (NSCLC). Molecular Cancer. 17: 52. PMID 29455675 DOI: 10.1186/S12943-018-0810-4 |
0.358 |
|
| 2017 |
Gelaleti GB, Borin TF, Maschio-Signorini LB, Moschetta MG, Jardim-Perassi BV, Calvinho GB, Facchini MC, Viloria-Petit AM, de Campos Zuccari DAP. Efficacy of melatonin, IL-25 and siIL-17B in tumorigenesis-associated properties of breast cancer cell lines. Life Sciences. PMID 28624391 DOI: 10.1016/J.Lfs.2017.06.013 |
0.383 |
|
| 2017 |
Gelaleti GB, Borin TF, Maschio-Signorini LB, Moschetta MG, Hellmén E, Viloria-Petit AM, Zuccari DAPC. Melatonin and IL-25 modulate apoptosis and angiogenesis mediators in metastatic (CF-41) and non-metastatic (CMT-U229) canine mammary tumour cells. Veterinary and Comparative Oncology. 15: 1572-1584. PMID 28322030 DOI: 10.1111/Vco.12303 |
0.409 |
|
| 2017 |
Jarad M, Kuczynski EA, Morrison J, Viloria-Petit AM, Coomber BL. Release of endothelial cell associated VEGFR2 during TGF-β modulated angiogenesis in vitro. Bmc Cell Biology. 18: 10. PMID 28114883 DOI: 10.1186/S12860-017-0127-Y |
0.433 |
|
| 2017 |
Leonel C, Borin TF, de Carvalho Ferreira L, Moschetta MG, Bajgelman MC, Viloria-Petit AM, de Campos Zuccari DA. Inhibition of Epithelial-Mesenchymal Transition and Metastasis by Combined TGFbeta Knockdown and Metformin Treatment in a Canine Mammary Cancer Xenograft Model. Journal of Mammary Gland Biology and Neoplasia. PMID 28078601 DOI: 10.1007/S10911-016-9370-7 |
0.395 |
|
| 2017 |
Pallegar NK, Mahendralingam M, Viloria-Petit A, Christian S. Abstract A18: A novel 3D co-culture system for the study of adipocyte and extracellular matrix influences on the breast cancer phenotype Cancer Research. 77. DOI: 10.1158/1538-7445.Epso16-A18 |
0.373 |
|
| 2016 |
Doerr M, Morrison J, Bergeron L, Coomber BL, Viloria-Petit A. Differential effect of hypoxia on early endothelial-mesenchymal transition response to transforming growth beta isoforms 1 and 2. Microvascular Research. 108: 48-63. PMID 27503671 DOI: 10.1016/J.Mvr.2016.08.001 |
0.444 |
|
| 2014 |
Adham SA, Al Rawahi H, Habib S, Al Moundhri MS, Viloria-Petit A, Coomber BL. Modeling of hypo/hyperglycemia and their impact on breast cancer progression related molecules. Plos One. 9: e113103. PMID 25401697 DOI: 10.1371/Journal.Pone.0113103 |
0.453 |
|
| 2014 |
Avery-Cooper G, Doerr M, Gilbert RW, Youssef M, Richard A, Huether P, Viloria-Petit AM. Par6 is an essential mediator of apoptotic response to transforming growth factor beta in NMuMG immortalized mammary cells. Cancer Cell International. 14: 19. PMID 24581220 DOI: 10.1186/1475-2867-14-19 |
0.357 |
|
| 2014 |
Gelaleti GB, Leonel C, Perassi-Jardim B, Ferreira L, Moschetta M, Borin T, Maschio L, Martins G, Viloria-Petit A, Zuccari D. P62. Effectiveness of melatonin, IL-25 and siRNA IL-17B in growth control of breast cancer cell lines Journal For Immunotherapy of Cancer. 2: 36. DOI: 10.1186/2051-1426-2-S2-P36 |
0.358 |
|
| 2013 |
Bane A, Viloria-Petit A, Pinnaduwage D, Mulligan AM, O'Malley FP, Andrulis IL. Clinical-pathologic significance of cancer stem cell marker expression in familial breast cancers. Breast Cancer Research and Treatment. 140: 195-205. PMID 23813303 DOI: 10.1007/S10549-013-2591-1 |
0.342 |
|
| 2012 |
Luga V, Zhang L, Viloria-Petit AM, Ogunjimi AA, Inanlou MR, Chiu E, Buchanan M, Hosein AN, Basik M, Wrana JL. Exosomes mediate stromal mobilization of autocrine Wnt-PCP signaling in breast cancer cell migration. Cell. 151: 1542-56. PMID 23260141 DOI: 10.1016/J.Cell.2012.11.024 |
0.393 |
|
| 2011 |
Prinz RD, Willis CM, Viloria-Petit A, Klüppel M. Elimination of breast tumor-associated chondroitin sulfate promotes metastasis. Genetics and Molecular Research : Gmr. 10: 3901-13. PMID 22183949 DOI: 10.4238/2011.December.8.9 |
0.436 |
|
| 2011 |
Kuczynski EA, Viloria-Petit AM, Coomber BL. Colorectal carcinoma cell production of transforming growth factor beta decreases expression of endothelial cell vascular endothelial growth factor receptor 2. Cancer. 117: 5601-11. PMID 21692070 DOI: 10.1002/cncr.26247 |
0.377 |
|
| 2010 |
Viloria-Petit AM, Wrana JL. The TGFbeta-Par6 polarity pathway: linking the Par complex to EMT and breast cancer progression. Cell Cycle (Georgetown, Tex.). 9: 623-4. PMID 20107326 DOI: 10.4161/Cc.9.4.10779 |
0.311 |
|
| 2009 |
Viloria-Petit AM, David L, Jia JY, Erdemir T, Bane AL, Pinnaduwage D, Roncari L, Narimatsu M, Bose R, Moffat J, Wong JW, Kerbel RS, O'Malley FP, Andrulis IL, Wrana JL. A role for the TGFbeta-Par6 polarity pathway in breast cancer progression. Proceedings of the National Academy of Sciences of the United States of America. 106: 14028-33. PMID 19667198 DOI: 10.1073/Pnas.0906796106 |
0.512 |
|
| 2006 |
du Manoir JM, Francia G, Man S, Mossoba M, Medin JA, Viloria-Petit A, Hicklin DJ, Emmenegger U, Kerbel RS. Strategies for delaying or treating in vivo acquired resistance to trastuzumab in human breast cancer xenografts. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 12: 904-16. PMID 16467105 DOI: 10.1158/1078-0432.Ccr-05-1109 |
0.519 |
|
| 2005 |
Ma L, Francia G, Viloria-Petit A, Hicklin DJ, du Manoir J, Rak J, Kerbel RS. In vitro procoagulant activity induced in endothelial cells by chemotherapy and antiangiogenic drug combinations: modulation by lower-dose chemotherapy. Cancer Research. 65: 5365-73. PMID 15958585 DOI: 10.1158/0008-5472.Can-04-3156 |
0.602 |
|
| 2004 |
Viloria-Petit AM, Kerbel RS. Acquired resistance to EGFR inhibitors: mechanisms and prevention strategies. International Journal of Radiation Oncology, Biology, Physics. 58: 914-26. PMID 14967451 DOI: 10.1016/J.Ijrobp.2003.09.091 |
0.542 |
|
| 2004 |
Zheng PS, Wen J, Ang LC, Sheng W, Viloria-Petit A, Wang Y, Wu Y, Kerbel RS, Yang BB. Versican/PG-M G3 domain promotes tumor growth and angiogenesis. Faseb Journal : Official Publication of the Federation of American Societies For Experimental Biology. 18: 754-6. PMID 14766798 DOI: 10.1096/Fj.03-0545Fje |
0.557 |
|
| 2003 |
Viloria-Petit A, Miquerol L, Yu JL, Gertsenstein M, Sheehan C, May L, Henkin J, Lobe C, Nagy A, Kerbel RS, Rak J. Contrasting effects of VEGF gene disruption in embryonic stem cell-derived versus oncogene-induced tumors. The Embo Journal. 22: 4091-102. PMID 12912908 DOI: 10.1093/Emboj/Cdg408 |
0.685 |
|
| 2002 |
Crombet-Ramos T, Rak J, Pérez R, Viloria-Petit A. Antiproliferative, antiangiogenic and proapoptotic activity of h-R3: A humanized anti-EGFR antibody. International Journal of Cancer. 101: 567-75. PMID 12237899 DOI: 10.1002/Ijc.10647 |
0.439 |
|
| 2001 |
Kerbel RS, Yu J, Tran J, Man S, Viloria-Petit A, Klement G, Coomber BL, Rak J. Possible mechanisms of acquired resistance to anti-angiogenic drugs: implications for the use of combination therapy approaches. Cancer Metastasis Reviews. 20: 79-86. PMID 11831651 DOI: 10.1023/A:1013172910858 |
0.683 |
|
| 2000 |
López-Ocejo O, Viloria-Petit A, Bequet-Romero M, Mukhopadhyay D, Rak J, Kerbel RS. Oncogenes and tumor angiogenesis: the HPV-16 E6 oncoprotein activates the vascular endothelial growth factor (VEGF) gene promoter in a p53 independent manner. Oncogene. 19: 4611-20. PMID 11030150 DOI: 10.1038/Sj.Onc.1203817 |
0.562 |
|
| 2000 |
Kerbel RS, Viloria-Petit A, Klement G, Rak J. 'Accidental' anti-angiogenic drugs. anti-oncogene directed signal transduction inhibitors and conventional chemotherapeutic agents as examples. European Journal of Cancer (Oxford, England : 1990). 36: 1248-57. PMID 10882863 DOI: 10.1016/S0959-8049(00)00092-7 |
0.627 |
|
| 1998 |
Kerbel RS, Viloria-Petit A, Okada F, Rak J. Establishing a Link between Oncogenes and Tumor Angiogenesis Molecular Medicine. 4: 286-295. DOI: 10.1007/Bf03401737 |
0.593 |
|
| Show low-probability matches. |